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ChildrenThe existence of multiple autoimmune disorders in diabetics may indicate underlying primary
defects of immune regulation. The study aims at estimation of defects of CD4+ CD25+high cells
among diabetic children with multiple autoimmune manifestations, and identiﬁcation of disease
characteristics in those children. Twenty-two cases with type 1 diabetes associated with other
autoimmune diseases were recruited from the Diabetic Endocrine and Metabolic Pediatric Unit
(DEMPU), Cairo University along with twenty-one normal subjects matched for age and sex as
a control group. Their anthropometric measurements, diabetic proﬁles and glycemic control
were recorded. Laboratory investigations included complete blood picture, glycosylated hemo-
globin, antithyroid antibodies, celiac antibody panel and inﬂammatory bowel disease markers
when indicated. Flow cytometric analysis of T-cell subpopulation was performed using anti-
CD3, anti-CD4, anti-CD8, anti-CD25 monoclonal antibodies. Three cases revealed a propor-
tion of CD4+ CD25+high below 0.1% and one case had zero counts. However, this observation
did not mount to a signiﬁcant statistical difference between the case and control groups neither
in percentage nor absolute numbers. Signiﬁcant statistical differences were observed between
the case and the control groups regarding their height, weight centiles, as well as hemoglobin
percentage, white cell counts and the absolute lymphocytic counts. We concluded that, derange-
ments of CD4+ CD25+high cells may exist among diabetic children with multiple autoimmune
manifestations indicating defects of immune controllers.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
Diabetes mellitus (DM) is a common chronic, metabolic syn-
drome; which results in hyperglycemia as a cardinal biochem-ical feature. Type 1 diabetes is the most common type of
diabetes in children and adolescents. Type 1 diabetes is caused
by deﬁciency of insulin secretion due to pancreatic B-cell dam-
age. Most cases of type 1 diabetes are primarily due to T-cell
mediated pancreatic islet b-cell destruction, which occurs at a
variable rate. There are usually serological markers of an auto-
immune pathologic process, including islet cell antibodies
(ICA), insulin autoantibodies (IAA), glutamic acid decarbox-
ylase (GAD), the insulinoma-associated 2 molecule (IA-
2)and zinc transporter 8 (ZnT-8) [1].
Autoimmune features were considered as associations with
immunodeﬁciency disorders but are now viewed as an
Table 1 Comparison between the case and control groups regarding their growth parameters: (Mann Whitney U test).
Number Median IQR P-value
Weight SDS Case 22 .700 3.4 0.05* (S)
Control 21 .100 2.1
Height SDS Case 22 1.250 3.2 0.004* (S)
Control 21 .200 1.9
IQR: Inter quartile range.
SDS: standard deviation score.
* P< 0.05.
648 D. S. Abd Elaziz et al.important component of some diseases attributed to the break-
down of self –tolerance or defects of immune regulators [2].
Furthermore some Primary Immune Deﬁciencies (PID) classi-
ﬁcations now divide diseases according to the frequency of
autoimmune features [3]. CD4+ CD25+ T cells were named
regulatory T cells (T reg) and since then have been intensively
characterized by many groups. It has now been well docu-
mented in a variety of models that CD4+CD25+ play indis-
pensable roles in the maintenance of natural self-tolerance, in
averting autoimmune responses, as well as in controlling
inﬂammatory reactions [4,5].
Type 1 diabetes is a common presenting feature in primary
immune deﬁciency disorders affecting immune control like
Immunedysregulation Polyendocrinopathy Enteropathy X-
linked syndrome (IPEX), Autoimmune Polyendocrinopathy
Candidiasis-Ectodermal dystrophy (APECED) and Common
Variable Immunedeﬁciency (CVID) [6,7]. The autoimmune
disorders are often present or can even prevail over recurrent
infections when the genetic defect affects regulatory T (Treg)
cells, which are the major players in maintaining peripheral
tolerance [8].
Treg cell subset is impaired in IPEX syndrome; a disease
caused by mutations in fork head box p3 (FOXP3) gene, the
master switch for the function of Treg cells [9]. Notably, around
one third of the patients, with clinical manifestation closely
resembling IPEX syndrome, FOXP3 is not mutated, these pa-
tients are referred to as IPEX like [10]. The contributions of
an altered Treg cell in the pathogenesis of IPEX like syndromesFig. 1 Comparison between cases and control groups regarding
their height on the Egyptian growth chart (percentiles).remain elusive [11]. Treg cell detection and quantiﬁcation in hu-
mans have been limited by the fact that themainmarkers of their
identiﬁcation, CD25+ and FOXP3+ are also expressed by the
activatedTeff cells, which can be increased in inﬂammatory con-
ditions, typically in autoimmune diseases [9,12].
The study aims at estimation of the defects of CD4+
CD25+high cells among diabetic children with multiple autoim-
mune manifestations, diagnosis of underlying primary immu-
nodeﬁciency disorders and indentiﬁcation of disease
characteristics in those children.
Subjects and methods
The study protocol was approved by the Institutional Review
Board and the Ethical Committee of Cairo University, Egypt
and informed consents were obtained from the patients’ guard-
ians. Twenty-two children (12 females and 10 males) with type
1 diabetes associated with other autoimmune diseases were en-
rolled from the Diabetic Endocrine and Metabolic Pediatric
Unit (DEMPU) of Cairo University from 2011 to 2012.
Inclusion criteria: Type 1 diabetes mellitus with one or
more of the following features: autoimmune enteropathy,
autoimmune thyroiditis, autoimmune hemolytic anemia, auto-
immune hepatitits and/or alopecia. Twenty-one healthy sub-
jects matched for age and sex were assessed as a control
group with no signs or symptoms of autoimmune, chronic,
inﬂammatory and neoplastic diseases.
Detailed history taking, clinical examination with emphasis
on anthropometric parameters and glycemic control over the
last year of the patients were taken. Laboratory investigations
included: complete blood picture, glycosylated hemoglobin,
antithyroid antibodies, Celiac antibody proﬁle and inﬂamma-
tory bowel disease proﬁle when indicated.
Peripheral venous blood was drawn using tubes containing
EDTA. Blood samples were processed within 2 h of collection.
Monoclonal antibodies
Phycoerythrin(PE)-conjugated monoclonal anti-CD4(Catalog
number FAB3791P), Phycoerythrin(PE)-conjugated monoclo-
nal anti-CD8 (Catalog number FAB1509P), ﬂuorescein isothi-
ocyanate (FITC)-conjugated anti-CD3(Catalog number
FAB100F) from R&D Systems Company and phycoerythrin
cyanin 5 (PE-cy5)-conjugated anti-CD25(Catalog number
555433) from BD Bioscience Company.
Flow cytometric analysis
Immunoﬂuorescence staining was performed on whole blood.
For each case; two test tubes were prepared; in each 50 ll of
Table 2 Clinical pattern and glycemic control in the case group.
No Age Onet of
DM
Clinical features Infections No of
DKA
Therapy HbA1c%
(mmol/ml)
CD4+
CD25+high
%
1 13.4 6.25 Hypothyroid HT, ST No 2 Thyroxin 10.8%(95) 0.44
2 7.7 2.55 Celiac, hypothyroid HT, ST Hepatitis A 1 Thyroxin 15%(140) 0.28
3 14.4 7.17 Celiac, Euthyroid HT, ST No 6 7.4%(57) 0.28
4 12.3 5.23 Euthyroid HT Sepsis (ICU) admission 2 9.5%(80) 0.45
5 10.9 8.63 Hypothyroid HT RTI 0 Thyroxin 7.2%(55) 0.36
6 11 4.42 Hypothyroid HT, ST No 1 Thyroxin 8.4%(68) 0.19
7 5.4 4.73 Hypothyroid HT No 1 Thyroxin 7.1%(54) 0.29
8 11.1 1.27 Celiac, Ulcerative colitis,
Euthyroid HT
URTI, Pneumonia, GIT with Entamoeba
histolytica
0 IS 8.4%(68) 0.07
9 12.1 0.2 Autoimmune hepatitis, ST,
(Wolcott-Rallison Syndrome)
Otitis media, Chicken Pox, Roseola infection
UTI with Klebsiella
1 IS 10.5%(91) 0.09
10 11.5 4.8 Hypothyroid HT No 0 Thyroxin 11.5% (102) 0.48
11 6.43 5.38 Euthyroid HT No 0 6.9%(52) 0.88
12 18.8 2.9 Celiac RTI >10 12.5% (113) 0.45
13 14.5 9.9 Celiac, ST RTI 1 13%(119) 0.38
14 12.44 9.7 Euthyroid HT Aplastic anemia,
SLE
EBV , CMV Oral moniliasis Wound infection
with Klebsiella and Pseudomonas
0 IS 5%(31) 0.0
15 10.09 9.2 Euthyroid HT No O 7.45%(58) 0.28
16 4.1 3 Euthyroid HT NO 0 7.4%(57) 0.43
17 15.58 12.3 Crohns disease Epiliptogenic
dysfunction by EEG
RTI Otitis media 0 IS 10.2%(88) 1.41
18 9.12 7.9 Euthyroid HT NO 1 9.6%(81) 0.07
19 14.15 8 Hypothyroid HT NO 1 Thyroxin 8.5%(69) 1.15
20 15.2 9.5 Euthyroid HT, Addison disease No 1 Asitonin H,
Hydrocortisone.
12.2% (110) 0.28
21 20.87 1 Hypothyroid HT, Alopecia,
neutropenia
Recurrent oral, vaginal ulcers and superﬁcial
abscess
0 Thyroxin 7.7%(61) 0.79
22 5.35 5.3 Hepatitis? Alopecia
Autoimmune hemolytic anemia
0 IS 6.3%(57) 0.47
Legend; DM: diabetes mellitus, DKA: diabetic ketoacidosis, HbA1c: glycosylated heamoglobin, HT: Hashimoto thyroiditis, RTI: respirator tract infection, URTI: upper respiratory tract infection,
GIT: gastroenteritis, IS: immunosuppressive drugs, EBV: Epstein barr virus, CMV: Cytomegalovirus, EEG: electroencephalogram, ST:sh rt stature, ICU: intensive care unit.
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650 D. S. Abd Elaziz et al.whole blood was added to the appropriate amount of the
monoclonal anti-bodies (5 ll).
Simultaneous staining for CD3, CD4, CD25 was done and
CD3 together with CD8 in the other tube.
Background ﬂuorescence was assessed using the appropri-
ate isotype- and ﬂuorochrome-matched control monoclonal
antibody to determine the percentage of positive cells. Lym-
phocytes were gated on by their forward and side scatter prop-
erties, and CD3+CD4+CD25+high cells were determined
within the lymphocytes gate.
Antibody staining analysis was performed on Beckman
Coulter Elite XL ﬂow cytometer FACSE.
These reagents were provided by Cairo University, there
was no other source of funding during conduction of the study
included.
Statistical analysis
Parametric quantitative data were presented by mean and
standard deviation (SD) and compared by t-student test.
Nonparametric quantitative data were presented by median
and interquartile range (IQR) and compared by Mann U
Whitney test. Continuous data were correlated by Pearson
correlation and presented by scatter plot. Receiver OperatorTable 3 Comparison between case and control groups regarding th
Group (n)
Hemoglobin (g/dl) Case (22)
Control (21)
WBC’s (·10.e3/ll) Case
Control
Neutrophil (%) Case
Control
ANC Case
Control
Lymph (%) Case
Control
ALC Case
Control
CD3+% Case
Control
Absolute no of CD3+ Case
Control
CD3+CD4+ % Case
Control
Absolute no of CD3+CD4+ Case
Control
CD3+CD8+ % Case
Control
Absolute no of CD3+CD8+ Case
Control
CD4+CD25+high % Case
Control
MFI Case
Contol
Absolute no of CD4+CD25+high Case
Control
WBC: white blood cells, ANC: absolute neutrophilic count.
ALC: absolute lymphocytic count.
The absolute count of CD4+CD25+ was done by Mann Whitney U test
* P< 0.05.Characteristic (ROC) curve were constructed to assess the
association between CD4+ CD25+ in relation to endocrinal
complication.
Results
The age of the patients ranged from 4.1 to 20.8 years (median
11.6). There were 10 males and 12 females. Consanguinity was
positive in six patients from the case group (27.3%). The aver-
age duration of diabetes was equal to ﬁve years and seven
months.
The ﬁrst presentation at diagnosis of diabetes mellitus
(DM) was Diabetic Ketoacidosis (DKA) in 18.2% of the pa-
tients and hyperglycemia in 81.8%. Six patients received
immunosuppressive drugs and eight patients received thyroxin
replacement. Most of our patients suffered acute diabetic com-
plications such as severe hypoglycemia (31.8%) and DKA
(54.6%). Regarding the hypoglycemic attacks, one patient
had frequent attacks of hypoglycemia before being diagnosed
as Addison disease, another patient was newly diagnosed,
whereas the other patients had infrequent attacks and were of-
ten related to their activity or receiving the dose of insulin
without taking the proper diet. Regarding the growth param-
eters there were signiﬁcant statistical differences between thee Hemoglobin, WBC’s and T cell subpopulations.
Mean SD P value
11.491 1.4527 0.01\
12.40 0.5128
6.464 3.0288 0.010\
8.524 1.7815
44.95% 12.124 0.441
47.52% 9.250
3108.77 2028.515 0.085
4039.10 1338.911
45.59% 11.927 0.724
44.48% 8.232
2763.55 1071.28 0.004\
3805.52 1153.876
63.364% 7.6100 0.348
60.810% 9.9257
1730.45 687.840 0.019\
2300.57 840.763
35.01% 7.1393 0.360
37.071% 7.4078
934.14 336.222 0.002\
1371.1 495.052
28.268% 6.7149 0.029\
23.762% 6.3231
800.55 428.011 0.415
901.81 374.601
0.430% 0.34913 0.82
0.4086% 0.2643
0.55 1.342 0.069
2.93 5.834
3.0412 3.73 0.099
4.2380 5.55
(Median, IQR), the others were done by T-test.
Fig. 2 Comparison of the absolute number of CD3+ CD4+ in
cases and control group.
Autoimmunity may indicate immune control defect 651case and control groups regarding their height, weight accord-
ing to the Egyptian growth chart, with P-value of 0.004, 0.05
respectively as shown in Table 1.
Seven patients were short in stature (below the 3rd percen-
tile for age and sex) as shown in Fig. 1. Cases numbers (2, 3)
were diagnosed as type 1DM, autoimmune thyroid disease
and Celiac disease. Cases numbers (1, 6) were diagnosed as
type1 DM and hypothyroid Hashimoto’s thyroiditis. Case
number (9) was diagnosed as type1 DM and Wolloct–Rallison
Syndrome. Case number (13) was diagnosed as type1 DM and
Celiac disease. Case number (22) was diagnosed as type1 DM
and autoimmune hemolytic anemia with alopecia. Six patients
also had delayed pubertal stages for their age cases no (1, 3, 4,
8, 9 and 13).Fig. 3 Flow cytometric results of patient 14: The lymphocyte, as it wa
for coexpression of CD4+ and CD25+high. CD4+CD25+high = 0%.The study group had poor glycemic control. Five patients
had glycosylated hemoglobin levels HbA1c >8.5%
(69 mmol/mol), while thirteen cases had HbA1c >8%
(64 mmol/mol), with duration of diabetes 5.73 years, SDS
(5.08), putting them at risk of the chronic complications of dia-
betes. Six of these patients (27.3%) had renal complication in
the form of persistent microalbuminuria or slight impairment
of the renal function, ﬁve of them had a duration of diabetes
>5 years cases no (1, 2, 8, 9 and 20) and only one patient with
3.2 years duration case no (14). The renal affection of the for-
mer patient cannot be contributed to diabetes alone as this pa-
tient had multiple autoimmune phenomena and was diagnosed
as Systemic Lupus Erythematosus (SLE). Two patients (9.1%)
suffered from neuropathy and one patient (4.5%) from
arthropathy.
The most frequent clinical autoimmune feature associated
with type 1 diabetes in the cases was endocrinopathy
(77.2%) in the form of Hashimoto’s thyroiditis with positive
antithyroid antibodies followed by enteropathy in 27.2% of
the cases. The celiac patients represented 22.7% of the total
patients whereas inﬂammatory bowel disease constituted 9%
(one patient had Celiac and Ulcerative colitis diseases, case
no 8). There was one case with autoimmune hepatitis, one case
with autoimmune hemolytic anemia and one case diagnosed as
Systemic Lupus Erythematosus (SLE) as demonstrated in
Table 2.
Regarding the blood counts in the case group, there were
three patients with leucopenia with white blood cell counts
(WBC) 6 4 · 10.e3/ll (cases # 2, 14, 17). There were ﬁve pa-
tients with neutropenia with absolute neutrophilic counts
(ANC) < 1500, case no 1(1290), case no 2(880), case no 14
(575), case no 17(816) and case no 21 (1300). There were two
patients with lymphopenia case no 8 with an absolute lympho-
cytic count (ALC) of (1222) and case no 17 (1344). Signiﬁcant
statistical differences were observed between case and control
groups regarding hemoglobin percentage, WBC’s and thes identiﬁed by their forward and side scatter properties were gated
Fig. 4 By analyzing the Roc curve of absolute CD4+ CD25+high it did not achieve under the curve >65% and it was of no signiﬁcant P-
value.
652 D. S. Abd Elaziz et al.absolute lymphocytic counts with P-values of 0.01, 0.01, 0.004,
respectively as shown in Table 3.
As for CD Counts, there were statistically signiﬁcant differ-
ences regarding the absolute CD3+ count, the absolute CD4+
counts and the CD8+ percentage results between the case and
control groups, with P-values of 0.019, 0.002 and 0.02 respec-
tively as seen in Table 3 and Fig. 2.
Four cases showedCD4+CD25+high percent less than
0.1%, (cases numbers 8, 9, 14 and 18), and their clinical fea-
tures as well as infection histories were described in Table 2.
The lower percentage of CD4+CD25+high was a continuous
not transient event, in case no (9) immunosuppressive treat-
ment was stopped ﬁve years ago before the study while in case
no (18) immunosuppressive drugs were never received, as for
case no (8) she was on Azathioprine and Pentaza during the
study and regardingcase no (14) he was on pulse steroid ther-
apy, Sandimmune and Cellcept. The ﬂow cytometry results of
patient number 14 show CD4+ CD25+%= 0% in Fig. 3.
There was no statistically signiﬁcant difference between the
two studied groups regarding the percentages or the absoluteFig. 5 Whisker and box plot comparison of the absolute counts
of CD4+ CD25+high in both cases and control groups.number of CD4+CD25+high by analysis of Roc curve as in
Fig. 4 and Fig. 5.
Also there was no statistically signiﬁcant difference between
mean ﬂuorescence intensity MFI in patients when compared to
the healthy group (See Fig. 6).Discussion
The consanguinity rate in the diabetic group was (27.3%),
higher rates were reported in Saudi diabetic children [13]. In
another study investigating cases with CD25+ deﬁciency, only
two male patients were described; one of them from a positive
consanguineous family [14].
In our study group, four patients (18.2%) presented by
DKA as a ﬁrst manifestation of T1DM, this frequency is lim-
ited to our group only, as it is lower than the frequency of
DKA being a ﬁrst presentation in Diabetic Endocrine and
Metabolic Pediatric Unit (DEMPU), which receives 30–50
newly diagnosed type1 diabetic patients monthly, with 30–
40% of them presenting with DKA (personal communica-
tion) as well as other studies with a range of 26.3–55.3%
[15,16].
Formerly, Type1 DM was known to have adverse effects on
linear growth and pubertal development [17]. However, with
recent insulin treatment regimens and monitoring of blood glu-
cose level, growth has substantially improved and height in
children with TIDM today should be similar in all ages to
the height of their unaffected peers [18].
The signiﬁcant statistical differences between the case and
the control groups regarding their height and weight point to
the multifactorial inﬂuence of their disease conditions, associ-
ations and treatment regimens. Five patients of them had gly-
cosylated hemoglobin levels (HbA1c) more than 8.5%, while
13 cases had HbA1c of more than 8% indicating poor control.
These results are in concordance with Danne et al. who
showed a direct correlation between increased glycosylated
heamoglobin levels and standing height SDS reduction [19]
and Gunczler et al. who also showed that children with poor
control have a signiﬁcantly lower growth velocity compared
with well controlled subjects [20].
Fig. 6 Flow cytometric results of patient 9: The lymphocyte, as it was identiﬁed by their forward and side scatter properties were gated
(a) for co expression of CD4+ and CD25+high. CD4+CD25+high = 0.09% (b) compared to one of the healthy controls (c and d) where
the CD4+CD25+high = 1.37%.
Autoimmunity may indicate immune control defect 653On the other hand, the development of chronic complica-
tions in diabetes is related to the hyperglycemia that persists
even with treatment of the disease, it is also dependent on
the duration of diabetes [21].
Our results showed that diabetic nephropathy was the most
common complication among this cohort of diabetic patients,
in concordance with other studies [22]. In contrast other stud-
ies reported a different incidence, where retinopathy was the
most common complication followed by neuropathy and
nephropathy [13].
Two patients (9.1%) had neuropathy, one patient with
duration of diabetes of 19.2 years case no (21) and the other
patient case no (14) was diagnosed as autoimmune
polyneuropathy.
Several autoimmune features were detected in some cases
necessitating vigilance to pick up those problems that maypresent in a subtle form in diabetics. Thyroid autoantibodies
ranked ﬁrst as the most commonly associated autoimmune dis-
order among diabetic patients in concordance with studies that
estimate percentage ranging from 11% to 46% of diabetic pa-
tients with either thyroid peroxidase antibodies or thyroglobu-
lin antibodies [23]. The prevalence of Celiac disease in patients
with diabetes ranges from 4.4% to 11.1% compared to the
general population [24,25]. In our study group the celiac pa-
tients represented 22.7% of the total patients whereas inﬂam-
matory bowel disease constituted 9% of the study group.
There was a signiﬁcant statistical difference between cases
and controls groups in hemoglobin percentage and white
blood counts with P-values (0.01, 0.01 respectively). These re-
sults are similar to those observed in laboratory abnormalities
in IPEX and IPEX like syndrome where cytopenia (anemia,
leucopenia, and thrombocytopenia) may be present [6,26].
654 D. S. Abd Elaziz et al.Regarding CD4+ CD25+high proportions, there were four
patients with values of less than 0.1% however values did
not mount to a statistical difference between the absolute num-
bers of CD4+ CD25+high cells between the control and cases
groups. These results were in concordance with Lindely et al.
and Putnam et al., who reported that there was no signiﬁcant
difference in the percentage of CD4+ CD25+high between pa-
tients and healthy subjects as well as in the level of
CD4+CD25+high expression per cell, when expressed as the
mean ﬂuorescence intensity [27,28] and are against Luczynski
et al. who found signiﬁcant statistical difference between newly
diagnosed type 1diabetes patients and normal children as re-
gards CD4+CD25+% but not the absolute counts **[29].
One explanation may be due to CD4+CD25+ expression by
the activated T effectors cell which can be increased in inﬂam-
matory and autoimmune diseases [12]. Another explanation is
that Treg may demonstrate reduced functional capacity with
drop of CD4+ CD25+ levels over time [30].
Other studies indicate the defect may involve the number
and/or function of Tregs in type 1 DM [31]. Barzaghi et al., re-
ported that CD4+ CD25+ FOXP3+ T cells median values ob-
tained in IPEX-like patients were not signiﬁcantly lower than
those detected in healthy controls, but by using demethylation
analysis of FOXP3 locus; results showed quantitative defect of
regulatory T cells in patients thanhealthy control with statisti-
cal signiﬁcance difference [11].
In case no 14, the patient was diagnosed as SLE while his
CD4+ CD25+% was zero. This patient suffered from poly-
neuropathy followed by diabetes then two years later he devel-
oped pancytopenia, with positive Anti nuclear Antibodies
(ANA), Anti double stranded Antibodies (Anti DNA), and
development of rapid renal affection with lupus cerebritis.
He also had positive anti-thyroglobulin antibodies and anti-
microsomal antibodies with normal thyroid function. This
ﬁnding was similar to most of studies that found a signiﬁcant
decreased percentage of CD4+ CD25+ cells in patients with
SLE as compared to healthy controls [32–34].
Other studies showed that patients who were untreated
and/or newly diagnosed with SLE, showed negative correla-
tion between percentage of CD4+CD25+ and the clinical
activity of the disease, this was also noted with pediatric pa-
tients and some studies reported an inverse correlation be-
tween number of CD4+CD25+ and disease activity as well
as autoantibody levels [33,35].
Limitations
Several study limitations were encountered, the small sample
size because of the rarity of the condition. The confounding ef-
fect of immunosuppressive therapy which could not be stopped
due to severity of the disease, functional Treg assays were not
conducted and might have explained why there were patients
with CD4+CD25+high similar to controls. Further studies with
Foxp3 expression need to be assessed as it is a key for Treg reg-
ulation mechanisms, using the demethylation methods.
Conclusions
In conclusion, diabetic children with multiple autoimmune fea-
tures may demonstrate CD4+CD25+high cells deﬁciency
favoring the immune disequilibrium.Conﬂict of interest
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